semaglutide and thyroid medication Novo Nordisk medicines containing There is no conclusive evidence

RetatrutideMounjaro (Tirzepatide)Wegovy (Semaglutide) Mechanism Triple (GLP-1 + GIP + Glucagon)Dual (GLP-1 + GIP)Single (GLP-1) Best weight loss in trials 30.3%22.5%20.7% Trial duration 104 weeks72 weeks72 weeks UK approval Not yetYes (Mounjaro)Yes (Wegovy) Injection frequency Once weeklyOnce weeklyOnce weekly One important caveat: the 30.3% figure comes from a 104-week trial, while the Mounjaro and Wegovy results are from 72-week trials

PI3K, phosphatidylinositol-3-kinase

The screening process is based on your self-reported information and the immediate results of their health screening (vitals, iron check)

Who's More Likely to Lose Hair on GLP-1